To date, the COG has only investigated a MEK inhibitor for acute leukemia through one of its registered studies, which is an ongoing Phase II trial of trametinib in r/r juvenile myelomonocytic leukemia (JMML). This evidence concerns the gene MAP2K7 and acute leukemia.